Arrowhead Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$22.34(as of Aug 28, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Arrowhead Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$22.34
Ticker SymbolARWR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees609
CountyUSA
Market Cap$3,012.6M
EBIDTA-85.4M
10-Day Moving Average20.86
P/E Ratio-20.93
20-Day Moving Average19.00
Forward P/E Ratio111.11
50-Day Moving Average17.55
Earnings per Share-1.20
200-Day Moving Average17.49
Profit Margin-631.11%
RSI70.74
Shares Outstanding138.3M
ATR1.05
52-Week High27.34
Volume2,476,962
52-Week Low9.57
Most Recent Support Level20.45
Book Value714.3M
Most Recent Resistance Level21.70
P/B Ratio4.35
Upper Keltner21.36
P/S Ratio5.21
Lower Keltner16.64
Debt-to-Equity Ratio21.36
Next Earnings Date12/01/2025
Cash Surplus-64.7M
Next Ex-Dividend DateUnknown

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Inc In Our Stock Scanner

As of Aug 29, 2025
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.